|
1
|
Bray F, Jemal A, Grey N, Ferlay J and
Forman D: Global cancer transitions according to the Human
Development Index (2008–2030): A population-based study. Lancet
Oncol. 13:790–801. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lordick F and Siewert JR: Recent advances
in multimodal treatment for gastric cancer: A review. Gastric
Cancer. 8:78–85. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bilici A: Treatment options in patients
with metastatic gastric cancer: Current status and future
perspectives. World J Gastroenterol. 20:3905–3915. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thijssen VL, Heusschen R, Caers J and
Griffioen AW: Galectin expression in cancer diagnosis and
prognosis: A systematic review. Biochim Biophys Acta. 1855:235–247.
2015.PubMed/NCBI
|
|
5
|
Wiersma VR, de Bruyn M, Helfrich W and
Bremer E: Therapeutic potential of galectin-9 in human disease. Med
Res Rev. 33(Suppl 1): E102–E126. 2013. View Article : Google Scholar
|
|
6
|
Fujihara S, Mori H, Kobara H, Rafiq K,
Niki T, Hirashima M and Masaki T: Galectin-9 in cancer therapy.
Recent Pat Endocr Metab Immune Drug Discov. 7:130–137. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hirashima M: Ecalectin/galectin-9, a novel
eosinophil chemo-attractant: Its function and production. Int Arch
Allergy Immunol. 122(Suppl 1): 6–9. 2000. View Article : Google Scholar
|
|
8
|
Matsumoto R, Matsumoto H, Seki M, Hata M,
Asano Y, Kanegasaki S, Stevens RL and Hirashima M: Human ecalectin,
a variant of human galectin-9, is a novel eosinophil
chemoattractant produced by T lymphocytes. J Biol Chem.
273:16976–16984. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Matsushita N, Nishi N, Seki M, Matsumoto
R, Kuwabara I, Liu FT, Hata Y, Nakamura T and Hirashima M:
Requirement of divalent galactoside-binding activity of
ecalectin/galectin-9 for eosinophil chemoattraction. J Biol Chem.
275:8355–8360. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saita N, Goto E, Yamamoto T, Cho I,
Tsumori K, Kohrogi H, Maruo K, Ono T, Takeya M, Kashio Y, et al:
Association of galectin-9 with eosinophil apoptosis. Int Arch
Allergy Immunol. 128:42–50. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Asakura H, Kashio Y, Nakamura K, Seki M,
Dai S, Shirato Y, Abedin MJ, Yoshida N, Nishi N, Imaizumi T, et al:
Selective eosinophil adhesion to fibroblast via IFN-gamma-induced
galectin-9. J Immunol. 169:5912–5918. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kageshita T, Kashio Y, Yamauchi A, Seki M,
Abedin MJ, Nishi N, Shoji H, Nakamura T, Ono T and Hirashima M:
Possible role of galectin-9 in cell aggregation and apoptosis of
human melanoma cell lines and its clinical significance. Int J
Cancer. 99:809–816. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kobayashi T, Kuroda J, Ashihara E, Oomizu
S, Terui Y, Taniyama A, Adachi S, Takagi T, Yamamoto M, Sasaki N,
et al: Galectin-9 exhibits anti-myeloma activity through JNK and
p38 MAP kinase pathways. Leukemia. 24:843–850. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kuroda J, Yamamoto M, Nagoshi H, Kobayashi
T, Sasaki N, Shimura Y, Horiike S, Kimura S, Yamauchi A, Hirashima
M, et al: Targeting activating transcription factor 3 by galectin-9
induces apoptosis and overcomes various types of treatment
resistance in chronic myelogenous leukemia. Mol Cancer Res.
8:994–1001. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fujita K, Iwama H, Sakamoto T, Okura R,
Kobayashi K, Takano J, Katsura A, Tatsuta M, Maeda E, Mimura S, et
al: Galectin-9 suppresses the growth of hepatocellular carcinoma
via apoptosis in vitro and in vivo. Int J Oncol. 46:2419–2430.
2015.PubMed/NCBI
|
|
16
|
Kobayashi K, Morishita A, Iwama H, Fujita
K, Okura R, Fujihara S, Yamashita T, Fujimori T, Kato K, Kamada H,
et al: Galectin-9 suppresses cholangiocarcinoma cell proliferation
by inducing apoptosis but not cell cycle arrest. Oncol Rep.
34:1761–1770. 2015.PubMed/NCBI
|
|
17
|
Nishi N, Itoh A, Fujiyama A, Yoshida N,
Araya S, Hirashima M, Shoji H and Nakamura T: Development of highly
stable galectins: Truncation of the linker peptide confers
protease-resistance on tandem-repeat type galectins. FEBS Lett.
579:2058–2064. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schutte B, Henfling M, Kölgen W, Bouman M,
Meex S, Leers MP, Nap M, Björklund V, Björklund P, Björklund B, et
al: Keratin 8/18 breakdown and reorganization during apoptosis. Exp
Cell Res. 297:11–26. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Masaki T, Tokuda M, Yoshida S, Nakai S,
Morishita A, Uchida N, Funaki T, Kita Y, Funakoshi F, Nonomura T,
et al: Comparison study of the expressions of myristoylated
alanine-rich C kinase substrate in hepatocellular carcinoma, liver
cirrhosis, chronic hepatitis, and normal liver. Int J Oncol.
26:661–671. 2005.PubMed/NCBI
|
|
20
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hartgrink HH, Jansen EP, van Grieken NC
and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Abe N, Watanabe T, Suzuki K, Machida H,
Toda H, Nakaya Y, Masaki T, Mori T, Sugiyama M and Atomi Y: Risk
factors predictive of lymph node metastasis in depressed early
gastric cancer. Am J Surg. 183:168–172. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamaguchi T, Sano T, Katai H, Sasako M and
Maruyama K: Node-positive mucosal gastric cancer: A follow-up
study. Jpn J Clin Oncol. 31:153–156. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
de Manzoni G, Verlato G, di Leo A,
Guglielmi A, Laterza E, Ricci F and Cordiano C: Perigastric lymph
node metastases in gastric cancer: Comparison of different staging
systems. Gastric Cancer. 2:201–205. 1999. View Article : Google Scholar
|
|
27
|
Jiang J, Jin MS, Kong F, Cao D, Ma HX, Jia
Z, Wang YP, Suo J and Cao X: Decreased galectin-9 and increased
Tim-3 expression are related to poor prognosis in gastric cancer.
PLoS One. 8:e817992013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang J, Zhu L, Cai Y, Suo J and Jin J:
Role of downregulation of galectin-9 in the tumorigenesis of
gastric cancer. Int J Oncol. 45:1313–1320. 2014.PubMed/NCBI
|
|
29
|
Yokozaki H: Molecular characteristics of
eight gastric cancer cell lines established in Japan. Pathol Int.
50:767–777. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Motoyama T, Hojo H and Watanabe H:
Comparison of seven cell lines derived from human gastric
carcinomas. Acta Pathol Jpn. 36:65–83. 1986.PubMed/NCBI
|
|
31
|
Kramer G, Erdal H, Mertens HJ, Nap M,
Mauermann J, Steiner G, Marberger M, Bivén K, Shoshan MC and Linder
S: Differentiation between cell death modes using measurements of
different soluble forms of extracellular cytokeratin 18. Cancer
Res. 64:1751–1756. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Morishita A, Gong J and Masaki T:
Targeting receptor tyrosine kinases in gastric cancer. World J
Gastroenterol. 20:4536–4545. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hilmi C, Larribere L, Giuliano S, Bille K,
Ortonne JP, Ballotti R and Bertolotto C: IGF1 promotes resistance
to apoptosis in melanoma cells through an increased expression of
BCL2, BCL-X(L), and survivin. J Invest Dermatol. 128:1499–1505.
2008. View Article : Google Scholar
|
|
34
|
Numata K, Oshima T, Sakamaki K, Yoshihara
K, Aoyama T, Hayashi T, Yamada T, Sato T, Cho H, Shiozawa M, et al:
Clinical significance of IGF1R gene expression in patients with
stage II/III gastric cancer who receive curative surgery and
adjuvant chemotherapy with S-1. J Cancer Res Clin Oncol. Sep
3–2015.(Epub ahead of print). http://dx.doi.org/10.1007/s00432-015-2039-6.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Galamb O, Sipos F, Molnar B, Szoke D,
Spisak S and Tulassay Z: Evaluation of malignant and benign gastric
biopsy specimens by mRNA expression profile and multivariate
statistical methods. Cytometry B Clin Cytom. 72:299–309. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ge J and Chen Z, Wu S, Chen J, Li X, Li J,
Yin J and Chen Z: Expression levels of insulin-like growth factor-1
and multidrug resistance-associated protein-1 indicate poor
prognosis in patients with gastric cancer. Digestion. 80:148–158.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yamada S, Kato S, Matsuhisa T,
Makonkawkeyoon L, Yoshida M, Chakrabandhu T, Lertprasertsuk N,
Suttharat P, Chakrabandhu B, Nishiumi S, et al: Predominant mucosal
IL-8 mRNA expression in non-cagA Thais is risk for gastric cancer.
World J Gastroenterol. 19:2941–2949. 2013.PubMed/NCBI
|
|
38
|
Lee KH, Bae SH, Lee JL, Hyun MS, Kim SH,
Song SK and Kim HS: Relationship between urokinase-type plasminogen
receptor, interleukin-8 gene expression and clinicopathological
features in gastric cancer. Oncology. 66:210–217. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee KE, Khoi PN, Xia Y, Park JS, Joo YE,
Kim KK, Choi SY and Jung YD: Helicobacter pylori and interleukin-8
in gastric cancer. World J Gastroenterol. 19:8192–8202. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Morishita A and Masaki T: miRNA in
hepatocellular carcinoma. Hepatol Res. 45:128–141. 2015. View Article : Google Scholar
|
|
41
|
Cui ZH, Shen SQ, Chen ZB and Hu C: Growth
inhibition of hepatocellular carcinoma tumor endothelial cells by
miR-204-3p and underlying mechanism. World J Gastroenterol.
20:5493–5504. 2014. View Article : Google Scholar : PubMed/NCBI
|
